Non-Small Cell Lung Carcinoma PD-L1 Positive
Item
histologically or cytologically confirmed diagnosis of non-small cell lung cancer (nsclc) that is pd-l1 positive per central laboratory review
boolean
C0007131 (UMLS CUI [1,1])
C4284303 (UMLS CUI [1,2])
Measurable lesion Quantity
Item
at least one measurable lesion.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Non-Small Cell Lung Carcinoma Progression Radiography | Therapy Double Platinum-Based | Disease TNM clinical staging | Recurrent disease
Item
radiographic progression of nsclc after treatment with a platinum-containing doublet for stage iiib/iv or recurrent disease
boolean
C0007131 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C0205173 (UMLS CUI [2,2])
C1514162 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C3258246 (UMLS CUI [3,2])
C0277556 (UMLS CUI [4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance scale 0 or 1
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
adequate organ function
boolean
C0678852 (UMLS CUI [1])
Cytotoxic Chemotherapy Systemic | Biological treatment | Major surgery
Item
systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks of the first dose of trial treatment
boolean
C0677881 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1531518 (UMLS CUI [2])
C0679637 (UMLS CUI [3])
Steroid therapy Systemic | Immunosuppressive Agents
Item
systemic steroid therapy within 3 days prior to the first dose of trial treatment or any other form of immunosuppressive medication
boolean
C0149783 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2])
Cancer treatment Systemic Required | Cancer treatment Localized Required
Item
expected to require any other form of systemic or localized antineoplastic therapy while on trial
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,3])
C0920425 (UMLS CUI [2,1])
C0392752 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
Malignant Neoplasms | Exception Basal cell carcinoma | Exception Superficial carcinoma of urinary bladder | Exception Squamous cell carcinoma of skin | Exception Carcinoma in Situ
Item
history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1336527 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C0007099 (UMLS CUI [5,2])
CNS metastases | Meningeal Carcinomatosis
Item
active central nervous system (cns) metastases and/or carcinomatous meningitis
boolean
C0686377 (UMLS CUI [1])
C0220654 (UMLS CUI [2])
Autoimmune Disease Requirement Systemic steroids | Autoimmune Disease Requirement Immunosuppressive Agents
Item
active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
boolean
C0004364 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C2825233 (UMLS CUI [1,3])
C0004364 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0021081 (UMLS CUI [2,3])
Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody
Item
prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-cytotoxic t-lymphocyte-associated antigen-4 (ctla-4) antibody
boolean
C1514463 (UMLS CUI [1])
C4289970 (UMLS CUI [2])
C4289971 (UMLS CUI [3])
C1705357 (UMLS CUI [4,1])
C0003250 (UMLS CUI [4,2])
C0214721 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C4289973 (UMLS CUI [6])
Lung Disease, Interstitial
Item
concurrent or past history of interstitial lung disease
boolean
C0206062 (UMLS CUI [1])
Pregnancy | Breast Feeding | Pregnancy Expected | Reproduction Expected
Item
pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study, starting with screening visit through 120 days after the last dose of pembrolizumab
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032961 (UMLS CUI [3,1])
C1517001 (UMLS CUI [3,2])
C0035150 (UMLS CUI [4,1])
C1517001 (UMLS CUI [4,2])